TAKEDA PHARMACEUTICALS AMERICA, INC.

Lobbying client · Massachusetts · filed 2025 to 2026

Pharmaceutical company

$9,300,000 Reported spend

47 Filings counted

7 Outside firms hired

25 Bills named

Spend is reported income plus in-house expenses across 47 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 8 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as TAKEDA PHARMACEUTICALS AMERICA INC.

Who filed for this client 8

TAKEDA PHARMACEUTICALS AMERICA, INC. $7,490,000 In-house, the client's own filings · 7 filings
HOLLAND & KNIGHT LLP $350,000 Outside firm · 7 filings
TIBER CREEK GROUP $350,000 Outside firm · 7 filings
TODD STRATEGY GROUP $350,000 Outside firm · 7 filings
CROSSROADS STRATEGIES, LLC $330,000 Outside firm · 7 filings
PORTERFIELD, FETTIG & SEARS, LLC $230,000 Outside firm · 5 filings
FARRAGUT PARTNERS LLP $130,000 Outside firm · 4 filings
AVENUE SOLUTIONS $70,000 Outside firm · 3 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 25

H.R. 1
One Big Beautiful Bill Act

13 filings
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

12 filings
S. 832
EPIC Act of 2025

7 filings
S. 891
Bipartisan Health Care Act

7 filings
H.R. 946
ORPHAN Cures Act

5 filings
H.R. 4229
To amend the Impoundment Control Act of 1974 to require prior approval from Congress before the Comptroller G…

4 filings
H.R. 2214
DRUG Act

3 filings
H.R. 1476
PLASMA Act

2 filings
H.R. 7299
To designate the facility of the United States Postal Service located at 2600 Michigan Avenue in Kissimmee, F…

2 filings
S. 694
PLASMA Act

2 filings
H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…

1 filing
H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

1 filing
H.R. 2528
Association Health Plans Act

1 filing
H.R. 4581
340B PATIENTS Act of 2025

1 filing
H.R. 5256
340B ACCESS Act

1 filing
H.R. 6609
Pharmacists Fight Back in Medicare and Medicaid Act

1 filing
H.R. 7837
Most Favored Patient Act of 2026

1 filing
H.R. 8269
CLEAR LABELS Act

1 filing
H.R. 9599
SECURE 340B Act

1 filing
S. 1040
Drug Competition Enhancement Act

1 filing
S. 1095
Stop STALLING Act

1 filing
S. 1096
Preserve Access to Affordable Generics and Biosimilars Act

1 filing
S. 1954
Biosimilar Red Tape Elimination Act

1 filing
S. 2372
340B PATIENTS Act of 2025

1 filing
S. 2658
Medication Affordability and Patent Integrity Act

1 filing

Reported by year 2 years

2026 $4,300,000 23 filings
2025 $5,000,000 24 filings

Issues lobbied 8

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 7

HOUSE OF REPRESENTATIVES 44
SENATE 35
Centers For Medicare and Medicaid Services (CMS) 4
Environmental Protection Agency (EPA) 2
Office of Management & Budget (OMB) 1
U.S. International Trade Commission (ITC) 1
U.S. Trade Representative (USTR) 1

Recent filings 48 total

Q3 report

AVENUE SOLUTIONS

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026

View → Q3 report

FARRAGUT PARTNERS LLP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026

View → Q3 report

TAKEDA PHARMACEUTICALS AMERICA, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $1,450,000 expenses · posted Oct 20, 2026

View → Q3 report

TIBER CREEK GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2026

View → Q3 report

TODD STRATEGY GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · $50,000 income · posted Oct 19, 2026

View → Q3 report

CROSSROADS STRATEGIES, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 17, 2026

View → Q3 report

HOLLAND & KNIGHT LLP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 7, 2026

View → Q2 report

TODD STRATEGY GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · $50,000 income · posted Jul 20, 2026

View → Q2 report

AVENUE SOLUTIONS

2nd Quarter 2026 (Apr 1 - June 30) · $20,000 income · posted Jul 20, 2026

View → Q2 report

TAKEDA PHARMACEUTICALS AMERICA, INC.

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $610,000 expenses · posted Jul 20, 2026

View → Q2 report

FARRAGUT PARTNERS LLP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $40,000 income · posted Jul 20, 2026

View → Q2 report

TIBER CREEK GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 19, 2026

View → Q2 report

CROSSROADS STRATEGIES, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 17, 2026

View → Registration

AVENUE SOLUTIONS

2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 15, 2026

View → Q2 report

HOLLAND & KNIGHT LLP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 10, 2026

View → Q1 report

FARRAGUT PARTNERS LLP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Jul 1, 2026

View → Registration

FARRAGUT PARTNERS LLP

1st Quarter 2026 (Jan 1 - Mar 31) · posted Jun 30, 2026

View → Q1 report

TODD STRATEGY GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · $50,000 income · posted Apr 20, 2026

View → Q1 termination

PORTERFIELD, FETTIG & SEARS, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 20, 2026

View → Q1 report

TAKEDA PHARMACEUTICALS AMERICA, INC.

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $1,410,000 expenses · posted Apr 20, 2026

View →

Showing the 20 most recent of 48 filings. Search the explorer for "TAKEDA PHARMACEUTICALS AMERICA, INC.".

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.